Scarica l'app Stockscreener
0.481
10.52%
0.0458
Dopo l'orario di chiusura:
.48
-0.001
-0.21%
Precedente Chiudi:
$0.4352
Aprire:
$0.44
Volume 24 ore:
536.59K
Relative Volume:
0.70
Capitalizzazione di mercato:
$26.92M
Reddito:
-
Utile/perdita netta:
$-151.16M
Rapporto P/E:
-0.162
EPS:
-2.97
Flusso di cassa netto:
$-130.08M
1 W Prestazione:
-4.51%
1M Prestazione:
-1.84%
6M Prestazione:
-64.10%
1 anno Prestazione:
-96.92%
Intervallo 1D:
$0.44
$0.481
Intervallo di 1 settimana:
$0.41
$0.5096
Portata 52W:
$0.41
$16.29
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Nome
Alx Oncology Holdings Inc
Settore
Industria
Telefono
650-466-7125
Indirizzo
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Confronta ALXO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
0.481 | 26.92M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-08 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-12-22 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-06 | Iniziato | UBS | Buy |
| 2021-02-10 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Iniziato | Credit Suisse | Outperform |
| 2020-08-11 | Iniziato | Jefferies | Buy |
| 2020-08-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Alx Oncology Holdings Inc Borsa (ALXO) Ultime notizie
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EG - GuruFocus
ALX Oncology to Host R&D Webcast Event Highlighting its - GlobeNewswire
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 - Stock Titan
HC Wainwright Issues Pessimistic Forecast for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
ALXO Stock: HC Wainwright & Co. Lowers Price Target | ALXO Stock News - GuruFocus
ALX Oncology Reports Q1 2025 Financial Results - TipRanks
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
ALXO Advances Cancer Therapy Focus and Pipeline Development | ALXO Stock News - GuruFocus
ALX ONCOLOGY Earnings Results: $ALXO Reports Quarterly Earnings - Nasdaq
Financial Health Check: Examining Alx Oncology Holdings Inc (ALXO)’s Key Ratios - DWinneX
ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ALX Oncology to Report First Quarter 2025 Financial Results on M - GuruFocus
ALX Oncology Holdings Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Will ALXO Make A Comeback In July? - RTTNews
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 | ALXO Stock News - GuruFocus
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Holdings Raised by JPMorgan Chase & Co. - Defense World
Geode Capital Management LLC Raises Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Was Alx Oncology Holdings Inc (ALXO)’s session last reading good? - uspostnews.com
Investor’s Delight: Alx Oncology Holdings Inc (ALXO) Closes Weak at 0.62, Down -4.90 - DWinneX
Alx Oncology Holdings Inc [ALXO] stock was sold by Pinto Shelly at the price of US$633.0 - knoxdaily.com
UBS Adjusts Price Target for ALX Oncology (ALXO) After Trial Out - GuruFocus
UBS Adjusts ALX Oncology Price Target to $1.20 From $2.20, Maintains Buy Rating - marketscreener.com
Market Momentum Report: Alx Oncology Holdings Inc (ALXO)’s Negative Close at 0.54 - DWinneX
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials - yahoo.com
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ALX Oncology faces Nasdaq delisting over price rule - Investing.com Australia
ALX Oncology (ALXO) Stock Dips After Phase 2 Trial Setback - GuruFocus
Evorpacept fails to meet trial endpoints in HNSCC - Investing.com
ALX Oncology faces Nasdaq delisting over price rule By Investing.com - Investing.com South Africa
ALX Oncology Announces Encouraging Final Results from Phase 1 Tr - GuruFocus
Sector Update: Health Care - marketscreener.com
Alx Oncology Holdings Inc: Rising -96.84% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
ALX Oncology (ALXO) Reports Promising Phase 1 Trial Results for Evorpacept in B-Cell Lymphoma | ALXO Stock News - GuruFocus
Evorpacept fails to meet trial endpoints in HNSCC By Investing.com - Investing.com South Africa
ALX Oncology Phase 1/2 Evorpacept Trial to Treat B-cell Non-Hodgkin Lymphoma Shows Anti-tumor Activity - marketscreener.com
ALX Oncology Reports Promising Phase 1 Results for Evorpacept in Combination with Rituximab and Lenalidomide in B-cell Non-Hodgkin Lymphoma at AACR 2025 - Nasdaq
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - GlobeNewswire
ALX Oncology stock falls on trial setback (ALXO:NASDAQ) - Seeking Alpha
ALX Oncology's Phase 2 Trials In Head & Neck Cancer Fail To Meet Primary Endpoints - Nasdaq
ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints - marketscreener.com
ALX Oncology (ALXO) Shares Update After Phase 2 Trials Yield Mixed Results | ALXO Stock News - GuruFocus
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evalua - GuruFocus
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials - GlobeNewswire
ALX Oncology's Evorpacept Falls Short in Dual Phase 2 Head and Neck Cancer TrialsWhat's Next? - Stock Titan
Sei Investments Co. Makes New Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALXO stock plunges to 52-week low of $0.48 amid market challenges - Investing.com India
ALXO stock plunges to 52-week low of $0.48 amid market challenges By Investing.com - Investing.com South Africa
Alx Oncology Holdings Inc Azioni (ALXO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):